FMXIN002
Type 1 allergic reactions (Anaphylaxis)
Phase 1Active
Key Facts
About Nasus Pharma
Nasus Pharma is a publicly traded, clinical-stage biotech company leveraging its intranasal delivery platform to create rescue therapies for severe allergic and immune-mediated conditions. Its lead program, FMXIN002 (intranasal epinephrine for anaphylaxis), has completed Phase I, targeting a significant market need for a needle-free alternative to auto-injectors. The company also has a second candidate, FMXIN007, for immunotherapy-related adverse events. With a low public market valuation and an early-stage pipeline, Nasus represents a high-risk, high-potential opportunity in the drug delivery space.
View full company profile